Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H12F6N4O |
| Molecular Weight | 450.3366 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=C(C=CC(C#N)=C2C(F)(F)F)N1CC3=NOC(=N3)C4=CC=CC(=C4)C(F)(F)F
InChI
InChIKey=ZEDODTZELVBHTG-UHFFFAOYSA-N
InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3
| Molecular Formula | C21H12F6N4O |
| Molecular Weight | 450.3366 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:26:43 GMT 2023
by
admin
on
Sat Dec 16 10:26:43 GMT 2023
|
| Record UNII |
8TFL50092H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
86620664
Created by
admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
|
PRIMARY | |||
|
1018971-95-3
Created by
admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
|
PRIMARY | |||
|
8TFL50092H
Created by
admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
|
PRIMARY | |||
|
GSK-971086
Created by
admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
|
PRIMARY | Official Title: A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers; Purpose: This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
SARM
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: GlaxoSmithKline; Mechanism of Action: Androgen receptor modulator; Highest Development Phase: No development reported for Muscular atrophy; Most Recent Event: 29 Apr 2011 No development reported - Phase-I for Muscular atrophy in USA (unspecified route)
|
